Franklin Genomic Advancements ETF
$43.83+0.00 (+0.00%)
- Expense ratio
- 0.50%
- Fund size
- $32M
- 1Y return
- +41.7%
- Yield · Last 12 months
- 0.33%
- Holdings
- 63
- Volume · 30D
- 0M sh
- NAV per share
- $43.09
- 52W range
The ETF.net HELX Grade
Score 37 of 100 sits in the D band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.DScore 38Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.CScore 40Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.DScore 31Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.CScore 41Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.CScore 41Category rank
Our read on HELX
DMost genomics funds hand you an index. Franklin's take is a stock-picker's portfolio of roughly 60 global names tied to gene sequencing, gene therapy and precision medicine, launched in 2020 with a plain mandate: capital appreciation.
The Fund seeks capital appreciation.
Why people hold it
- A concentrated bet, not a basket: about 60 global holdings across the genomics chain, so individual breakthroughs actually move the fund instead of being diluted by hundreds of names.
- Global by design. The mandate is not fenced to US listings, which matters in a field where sequencing and gene-therapy leaders sit in Europe and Asia too.
- Fee sits right at the middle of the genomics and biotech peer group at 0.50%, so you are not paying a premium over the typical thematic competitor for a discretionary approach.
- Live since 2020, giving it a multi-year record through a brutal stretch for biotech, rather than a launch-window track record.
Worth knowing
- It is a small, thinly traded fund. Use limit orders, expect wider spreads than the big index names, and know that small ETFs carry more closure risk than entrenched ones.
- The low-cost, high-liquidity lane in this category belongs to index products like IBBQ (0.19%) and IBB (0.44%). HELX's case rests on the manager's picks, not on price or trading ease.
- Genomics is a growth-style, high-volatility corner of health care. Clinical trial results and rate moves can swing a 60-stock portfolio hard in both directions.
HELX Holdings
- Stocks
- 63
- 49%
- GH
Sectors
- Health Care96.5%
- Materials2.6%
- Technology0.8%
Geography
- United States89.64%
- Netherlands2.14%
- Germany2.03%
- United Kingdom1.98%
- Ireland1.42%
- Switzerland1.21%
- South Korea1.02%
- Denmark0.55%
HELX Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | HELX |
|---|---|
| Year to date | +20.6% |
| 1 month | +1.6% |
| 3 months | +20.6% |
| 1 year | +41.7% |
| 3 years | +15.9% |
| 5 years | −4.9% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | HELX |
|---|---|---|
| 2026 YTD | +20.6% | |
| 2025 | +26.4% | |
| 2024 | −5.3% | |
| 2023 | +1.1% | |
| 2022 | −37.9% | |
| 2021 | +9.8% | |
| 2020 | +85.1% |
HELX in the news
ETF.net Research hasn’t filed on HELX yet — coverage lands here as it’s written.
HELX Dividends
- 0.33%
- $0.14
- $0.14 per share
- Irregular
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Dec 30, 2025 | Jan 8, 2026 | $0.14 |
| Dec 30, 2021 | Jan 7, 2022 | $0.0039 |
| Dec 13, 2021 | Dec 21, 2021 | $0.11 |
| Dec 14, 2020 | Dec 23, 2020 | $0.05 |
HELX Risk
- 22.3%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.37
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −58.2%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.98
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
HELX Cost
- The middle half of Biotech & Genomics funds
- Median 0.47%
8 of the 15 Biotech & Genomics funds charge less.